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Sample handling of gastric tissue 
and O-glycan alterations in paired 
gastric cancer and non-tumorigenic 
tissues
Barbara Adamczyk1, Chunsheng Jin1, Karol Polom2,3, Pedro Muñoz4, Miguel A. Rojas- Macias1, 
David Zeeberg5, Mats Borén5, Franco Roviello6 & Niclas G. Karlsson1
Sample collection, handling and storage are the most critical steps for ensuring the highest preservation 
of specimens. Pre-analytical variability can influence the results as protein signatures alter rapidly after 
tissue excision or during long-term storage. Hence, we evaluated current state-of-the-art biobank 
preservation methods from a glycomics perspective and analyzed O-glycan alterations occurring in 
the gastric cancer tissues. Paired tumor and adjacent normal tissue samples were obtained from six 
patients undergoing gastric cancer surgery. Collected samples (n = 24) were either snap-frozen or heat 
stabilized and then homogenized. Glycans were released from extracted glycoproteins and analyzed 
by LC-MS/MS. In total, the relative abundance of 83 O-glycans and 17 derived structural features were 
used for comparison. There was no statistically significant difference found in variables between snap 
frozen and heat-stabilized samples, which indicated the two preservation methods were comparable. 
The data also showed significant changes between normal and cancerous tissue. In addition to a shift 
from high sialylation in the cancer area towards blood group ABO in the normal area, we also detected 
that the LacdiNAc epitope (N,N’-diacetyllactosamine) was significantly decreased in cancer samples. 
The O-glycan alterations that are presented here may provide predictive power for the detection and 
prognosis of gastric cancer.
Glycomics is an emerging scientific discipline that seeks to understand the structure and function of gly-
cans in biological systems. Glycan biosynthesis is a post-translational modification (PTM) and is not directly 
template-driven. Therefore, multiple factors can impact the glycosylation process, including glycosyltransferases 
accessibility to glycosylation modification sites, availability of sugar-nucleotide precursors, transport rates of gly-
coproteins from the ER to Golgi, enzyme levels or localization of enzymes that can compete for the same glycan 
substrates1,2. Many physiological changes are mediated by PTMs and cannot be predicted from the nucleic acid 
sequence. Aberrant glycosylation has been reported in many diseases such as rheumatoid arthritis, congenital dis-
orders of glycosylation, and cancer, to name but a few3–6. However, due to the complexities in glycan biosynthesis, 
there are significant analytical challenges associated with the analysis of glycans in clinical samples7.
Sampling procedure is often the first but often the most critical step for ensuring the highest preservation 
of samples and the best quality for pre-clinical, translational or clinical projects. Good sampling and sample 
preparation influence the robustness and performance of analytical methods8. However, these steps are often 
overlooked, and most of the emphasis is placed on the development of an analytical method. When tissue sample 
is removed from its native environment, several alterations at the molecular level occur due to absence of vascular 
perfusion, ischemia, hypoxia, accumulation of cellular waste, absence of electrolytes and temperature changes9. 
In addition to stress associated with tissue excision, variability during collection procedures, delay in sample 
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freezing, degradation following sample collection or freeze/thaw cycles can influence quality and quantity of pro-
teins/glycoproteins in these matrices. Universal approach for sample preservation involves application of protease 
inhibitors and cold temperature/freezing.
Another preservation technology has been developed combining convective heating under controlled pres-
sure that stop degradation and alterations immediately and permanently10. Benefits of using this platform have 
been demonstrated for small molecules, lipids, endogenous peptides and phosphoproteins11–14. Several studies 
have been conducted concerning the stability of proteins and phosphoproteins post excision15,16 but to the best 
of our knowledge, stability of glycoproteins has not previously been examined. Some of the glycan residues may 
be prone to degradation, for example desialylation, desulfation and de-O-acetylation. The problem associated 
with sialic acid and its labile nature has been addressed by developing chemical derivatization approaches17–19. 
However, analysis of underivatized glycans is still commonly used in glycoproteomic and glycomic studies20–22.
Elucidating the role of proteins and their post-translational modifications is crucial to understand biological 
mechanisms and define potential biomarkers. Exploiting the differences in glycan repertoires between cancerous 
and normal tissues provides opportunities to discover new targets for personalized cancer diagnosis and treat-
ment. Discovery of these cancer-associated modifications of glycans on the glycoproteins may also improve on 
the specificity of existing cancer biomarkers. Gastric cancer (GC) is a major worldwide cancer burden with almost 
1 million cases in 2012 and an annual mortality rate of approximately 723,00023. The treatment is most effective 
in the initial stage of the disease and hence early detection could reduce mortality. Although screening methods 
currently used in the clinic for GC improved in the recent past, they are still expensive, invasive and/or uncom-
fortable for the patients. Several serological assays are used in GC diagnosis and prognosis, e.g., CEA, CA19-9, 
CA72-4 and CA50 but they often lack sensitivity and specificity24,25. Thus, there is still an unmet need for the 
development of accurate biomarkers for the early detection and follow-up of gastric cancer patients. Alterations 
of glycan structures can influence their interactions with glycan-binding proteins and as a result affect cellular 
processes, such as tumor progression, metastasis and recognition by the immune system26. Hence, adding infor-
mation on glycan changes to screening of protein levels is an attractive approach.
With glycomics being a relatively young area of research, we are just starting to learn how to utilize avail-
able biobanks for glycomic analysis. Biobanks and archived data sets have become crucial resources for many 
studies relying on sample collections with associated clinical and pathological data. Many population-based and 
disease-based biobanks have been formed, and more are under development27,28. These large-scale repositories 
will play an important role for investigating human diseases by omics technologies. The suitability of biologi-
cal samples collected in the past and currently stored in biobanks is unknown. In proteomics, there has been 
concern that variability related to pre-analytical delays can impact the results as protein signatures alter rapidly 
when tissues experience the traumatic event of excision or samples are stored over prolonged periods. Hence, we 
evaluated current state-of-the-art biobank preservation methods from a glycomics perspective. We examined 
the effect of snap freezing versus heat-stabilization technology on gastric O-glycans and O-glycan alterations 
occurring in the gastric cancer tissues in comparison to adjacent normal mucosa. By further defining the gastric 
cancer specific glycosylation utilizing the O-linked technology platform, more accurate monitoring of the gastric 
carcinogenesis processes can be achieved.
Results
Method optimization. The main goal of sample homogenization is to solubilize as many proteins as possi-
ble from a tissue for the full representation of the proteome (glycoproteome). Aiming to select the best conditions 
for efficient extraction of proteins from tissue samples, we evaluated a) manual vs. semi-automatic homogeni-
zation b) solubilisation buffers with two different detergents – the ionic SDS and zwitterionic CHAPS and c) 
whether sonication was an essential step to solubilize tissue. Due to a very precious clinical material, we have 
optimized the protocol on porcine gastric tissue. Three different tissue homogenization and extraction steps were 
optimized using either the Precellys 24, Ultra Turrax T10 homogenizer with dispersing element S10N-5G and 
a sonicator probe. Efficient tissue homogenization is a prerequisite for optimal protein extraction and is often 
performed manually, one sample at a time. However, this approach is very tedious and often prone to errors and 
diminished reproducibility. To increase speed and reproducibility we tested homogenization tubes with ceramic 
beads for automated tissue homogenization. There are several types of homogenization tubes and beads available 
from instrument manufactures. The tubes, the time and power settings needed for homogenization depend on 
the tissue type but since gastric tissue is rather a tough tissue we decided to use 2 mL reinforced propylene tubes in 
combination with 3-mm ceramic beads as these have been showed previously to withstand the high power setting 
(5000) during 2–3 × 20 sec cycles on Precellys system29,30. These were evaluated previously for lipid extraction29. 
We did not observe any significant differences between manual and semi-automatic homogenization (data not 
shown).
Urea-based buffers are widely used for sample homogenization and has been shown to provide higher pro-
tein yields than non-urea buffers31. Therefore, we decided to use urea-based buffer and optimize concentration 
of detergents to facilitate recovery of O-glycans from gastric tissue. We have tested SDS and CHAPS. Figure 1 
represents the full range LC-MS spectral profiles as well as enlarged area of lower mass range. The resulting data 
showed very similar relative abundance of O-glycan structures. However, we found that samples solubilized in 
SDS (Fig. 1C,D) provided lower background than samples solubilized in CHAPS (Fig. 1A,B). The difference was 
especially evident for the lower mass range (m/z 380–700). Although extracted ion chromatograms were of sim-
ilar quality (data not shown), interfering signals in CHAPS samples could contribute to lower resolving power 
and a decreased reliability of quantification. The effect of interfering signals was measured using signal-to-noise 
(S/N) ratio with peak detection ICIS algorithm using Xcalibur software. High abundant ions had similar S/N 
ratio for SDS and CHAPS samples but ions of lower abundance displayed higher variance. In particular, CHAPS 
treated samples presented lower S/N rations for low molecular oligosaccharide peaks with [M - H]-ions of m/z 
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464.5 (Hex1HexNAc1Sulfate1) (mean = 29), m/z 667.5 (Hex1HexNAc2Sulfate1) (mean = 151), and m/z 675.5 
(NeuAc1Hex1HexNAc1) (mean = 140) than the SDS-treated samples (mean = 51; mean = 201; mean = 191, 
respectively). Moreover, to further optimize the method, we have tested different concentration of SDS in the 
solubilisation buffer (0.5%, 1% and 2%) and the resulting data were very similar (data not shown).
Figure 1. Comparison of LC-MS spectra of O-linked glycans released from porcine gastric tissue 1) 
CHAPS + sonication, 2) CHAPS without sonication, 3) SDS with sonication 4) SDS without sonication. (A) LC-
ESI-MS profiles showing a full m/z range (380–2000), panels on the right illustrate an enlarged region of m/z 450–
700, region that differ between the samples is highlighted in grey. Major glycan peaks are labeled with m/z values 
and compositions (H, Hexose; HN, N-acetylhexosamine; S, Sialic acid (N-acetylneuraminic acid); Sf, Sulfate).
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Since our protocol included an overnight solubilisation of the samples, at 4 °C with detergent and reducing 
agent, sonication did not prove to be of added benefit. The LC-MS profile of O-linked glycans is very similar with 
and without the sonication as shown in Fig. 1. Elimination of sonication step in the protocol speeds up the process 
without compromising on the quality of analyses.
Analysis of porcine gastric tissue samples using different conditions showed no major differences between 
the O-glycome. Therefore, to minimize variations and increase the speed and reproducibility of the analyses we 
decided to proceed with solubilisation buffer containing SDS and semi-automatic homogenization with Precellys 
system without sonication step.
The O-glycans in human gastric tissue. O-glycans from 6 individuals (Figure 2 and Table 1) were 
released from human gastric tissue by reductive β-elimination and were analyzed using LC-ESI-MS/MS. The 
resulting data was aligned, peaks picked and quantified with an aid of Progenesis QI software. All structures 
were manually annotated using monoisotopic precursor mass and CID-based MS/MS fragmentation. Intensities 
were converted to relative % abundance for every structure and log-transformed (Tables S1 and S2). In addition, 
several glycosylation features, based on the data and knowledge on carcinoma associated epitopes (Table S1), 
were derived from ratios of the glycan peaks, summing up all structures that contained the same structural 
trait, namely sialylation, sulfation, fucosylation, neutral glycans (Hex + HexNAc only), LacdiNAc (GalNAcβ1-
4GlcNAc), and epitopes such as Lewisa/x, Lewisb/y, αGlcNAc, I branch, blood group H, A and B. Furthermore, 
mass spectrometry average compositions (Table S1) were calculated. Examples of fragmentation spectra and 
annotation for sialylated glycan with an [M – H]- ion of m/z 878 (NeuAc1Hex1HexNAc2), LacdiNAc containing 
structure with an [M – H]- ion of m/z 936 at 23.8 min (Hex1HexNAc3dHex1) and H blood epitope containing 
glycan with an [M – H]- ion of m/z 1041 (Hex2HexNAc2dHex2) are represented in Fig. 3.
The resulting data confirmed the presence of at least 83 O-linked glycan structures and 17 derived features 
were examined to compare the O-glycosylation in human gastric tissue (Tables S1 and S2). Among identified 
Figure 2. Overview of the workflow for O-glycan analysis from gastric tissue samples using LC-MS/MS.
ID Gender Age Blood Group Stage Diameter (mm) Lauren
1 Male 86 AB Rh+ IIIB 75 INT
2 Female 84 O Rh- IIIC 40 MIX
3 Male 67 A Rh- IIB 50 MIX
4 Male 85 O Rh+ IIIA 65 INT
5 Female 85 A Rh- IIIB 60 INT
6 Female 91 A Rh+ IIB 55 INT
Table 1. Clinical characteristics of the patients.
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structures, the majority was found to be core 2 O-glycans. Core 1, core 3 and core 5 were also present but they 
were of lower abundance (Table S1). The glycan chain length was between two and eleven monosaccharides.
Sample handling post collection - snap frozen vs. heat stabilized. A dataset of identified structures 
from four groups of tissue samples, normal - standard conditions (A), cancer - standard conditions (B), normal 
heat-stabilized post-collection (C) and cancer heat-stabilized post-collection (D) was generated as described in 
Fig. 2. No MS intensities from these structures were found to be statistically significant between normal standard 
(A) and normal heat-stabilized (C) samples as well as between cancer standard (B) and cancer heat-stabilized (D) 
(Table S2). In order to display this we generated the MS intensity correlation between different groups of samples 
using linear regression analysis. Coefficient of determination (denoted as R2) indicates how well all data points 
Figure 3. Examples of LC-MS/MS fragmentation spectra of glycan (A) sialylated structure with composition 
NeuAc1Hex1HexNAc2 [M-H]- ion of m/z 878, (B) LacdiNAc containing O-glycan with composition 
dHex1Hex1HexNAc3 [M-H]- ion of m/z 936. (C) Blood group H epitope containing glycan with composition 
dHex2Hex2HexNAc2 [M-H]- ion of m/z 1041. Proposed structures are depicted using SNFG nomenclature63 
and fragments of carbohydrates as defined by Domon and Costello64.
www.nature.com/scientificreports/
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fall on the regression line. As shown on Fig. 4, variation between snap frozen and heat stabilized samples is very 
low, for normal samples R2 = 0.99 (Fig. 4A) and for cancer samples R2 = 0.95 (Fig. 4B). These data suggest that 
O-glycans are not influenced by the difference in stabilization methods. Notably, correlation between normal 
samples is higher than for cancer samples. It has been shown before32 and also our data suggest that cancerous 
O-glycans are more variable due to the different staging, local heterogeneity and histological manifestation of 
cancer. Hence, the lower R2 found in the cancer sample is probably reflecting a microheterogenetity between the 
paired cancer samples rather that a difference in the sample preservation method.
In addition, we also examined differences in the structural features derived from the the identified structures. 
Box-plots displayed in Figs 5 and 6 confirmed that the O-glycans in snap-frozen and heat-stabilized samples was 
very similar. Hence, the conclusion is that the O-glycans did not differ between snap-frozen and heat-stabilized 
samples suggesting that heat stabilization is a good alternative for biobank preservation for glycomics and do not 
contribute to any unwanted degradation.
Differences between normal and cancerous tissue O-glycome. The subsequent phase of the study 
was aimed at identification of O-glycans that were altered between normal and cancerous tissue. Statistical anal-
ysis was carried out in order to detect any changes in glycosylation. A returned p value less than 0.05 was used as 
a first screen and relevance of observed alterations was further examined using box-plots. In total, 9 out of the 
83 O-glycan structures and 1 out of 17 calculated structural features were returned as being altered for normal 
and cancerous samples (Table S1). In addition, 8 glycan structures and 3 calculated features reached a p value of 
0.1 and showed decreasing or increasing trend between sample classifications. To evaluate the trends further, 
box-plots were generated. Figure 5A displays results for log-transformed sum of the derived features that were 
different between normal and cancerous samples. The most significant difference can be seen for the LacdiNAc 
epitope (p = 0.013 for AB groups (snap frozen) and p = 0.015 for CD groups (heat stabilized). Of note from 
Fig. 5A is also an increasing trend for sialylated structures in cancerous tissue (p = 0.1) and a decreasing trend for 
fucosylated structures and H type epitope containing structures (p = 0.06 and p = 0.10, respectively). Also of note 
is the distribution within each box-plot, tight for normal samples and with higher spread for cancerous samples, 
which can indicate higher diversity within different subtypes or stages of gastric cancer. Similar trends between 
normal and cancerous samples are seen for levels of mass spectrometry average composition (Table S1).
Figure 4. Correlation between samples using linear regression analysis (A) Normal samples – std vs heat 
stabilized, (B) Cancer samples – std vs. heat stabilized. These plots represent log-transformed data of the mean 
value for 88 variables for specified groups of samples.
Figure 5. Boxplots representing distribution of log-transformed data (A) derived structural features that 
differed between normal and cancerous samples (B) derived structural features that were of similar abundance 
between normal and cancerous samples. Min to max value of derived features is plotted along with all points to 
show the distribution of variable, statistically significant difference is included as p value; also p-values below 0.1 
are displayed showing trends in the data.
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Figure 6. Change in glycosylation between normal and cancerous tissue samples. Only those box plots of 
glycan structures that were found to change significantly are shown here. (A) m/z 878, (B) m/z 936, (C) m/z 
1041, (D) m/z 1260, (E) m/z 1406 and (F) m/z 1917. Data are given in a boxplot to show the spread of individual 
values. The diagram is made up of a ‘box’, which lies between the upper and lower quartiles. The median level 
divides the ‘box’ into two. The ‘whiskers’ extend from the ends of the box to the maximum and minimum 
values, respectively. Values for normal tissues are shown in green color (lighter for snap frozen samples, 
darker for heat-stabilized) and cancer tissues are shown in red (lighter for snap frozen samples, darker for 
heat-stabilized). The glycan structures are denoted using SNFG notation63. Statistically significant difference is 
included as p value; also p-values below 0.1 are displayed showing trends in the data.
www.nature.com/scientificreports/
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Analysis of the individual glycan structures showed several alterations in glycosylation between normal 
and cancerous samples. Nine glycans out of 83 had p value less than 0.05 and six with the lowest p value are 
depicted in Fig. 6. Alterations were identified in structures containing sialic acid, blood H-type epitope and 
LacdiNAc. Specifically, the levels of m/z 878 (NeuAcα2,3Galβ1,3(GlcNAcβ1,6)GalNAcol) were higher in can-
cerous samples (0.27 ± 0.07%, mean ± SEM in normal samples to 0.54 ± 0.09% in cancerous tissues) (Fig. 6A). 
Similarly, the levels of m/z 675 (Galβ1,3(NeuAcα2,6)GalNAcol and NeuAcα2,3Galβ1,3GalNAcol), m/z 966 
(NeuAcα2,3Galβ1,3(NeuAcα2,6)GalNAcol), and m/z 1331 (NeuAcα2,3Galβ1,3(NeuAcα2,3Galβ1,4GlcNAcβ1,6)
GalNAcol) were also increased in cancerous samples, although with a p > 0.1 (1.40 ± 0.19%, mean ± SEM in nor-
mal samples to 3.35 ± 0.93% in cancerous samples; 2.75 ± 0.42% in normal samples to 6.57 ± 1.83% in cancerous 
samples; 1.70 ± 0.20% in normal samples to 5.69 ± 1.91% in cancerous samples; 0.51 ± 0.05% in normal samples 
to 3.35 ± 1.24% in cancerous samples, respectively).
Interestingly, a decrease in a biantennary structure containing both blood group H as well as a LacdiNAc 
epitope with an [M – H] of m/z 936 (Fucα1,2Galβ1,3(GalNAcβ1,4GlcNAcβ1,6)GalNAcol) was also observed 
(Fig. 6B); higher levels of this structure were present in normal samples than those in the cancerous condition 
(2.64 ± 0.60%, mean ± SEM vs. 0.97 ± 0.23%, mean ± SEM). In addition to m/z 936, two more structures have 
been identified to contain LacdiNAc eptiope, m/z 790 (Galβ1,3(GalNAcβ1,4GlcNAcβ1,6)GalNAcol) and m/z 1139 
(GalNAcα1,3(Fucα1,2)Galβ1,3(GalNAcβ1,4GlcNAcβ1,6)GalNAcol). Both, were of higher abundance in normal 
tissues in comparison to cancerous samples (1.34 ± 0.26%, mean ± SEM in normal vs. 0.97 ± 0.14%, mean ± SEM 
in cancer, 0.76 ± 0.18%, mean ± SEM in normal vs. 0.51 ± 0.15%, mean ± SEM in cancer, respectively).
Four glycan structures ([M – H]- ions of m/z 1041 (Hex2HexNAc2dHex2), m/z 1260 (Hex3HexNAc3dHex1), 
m/z 1406 (Hex3HexNAc3dHex2), and m/z 1917 (Hex4HexNAc4dHex3)) were decreased (p < 0.1 in AB and/or CD 
set) in cancerous tissue samples (Fig. 6C–F and Table S2). All of them contain blood H type epitope, α1,2 fucose 
residue.
Intrigued by all the trends in the change of glycosylation between healthy and cancerous tissue seen already 
by analyzing only six individuals, additional samples and analysis will be required for verification of the findings. 
Stringent statistical evaluation requires a larger clinical sample set when a large number of variables (n = 100 (83 
structures +17 derived features)) are evaluated. This is illustrated in our data were the significance levels of the 
paired sample t-tests on glycosylation structures and features were further corrected for multiple comparison and 
adjusted p-values (q-values) increased (Tables S1 and 2). In all figures, we present non-adjusted p-value to show 
only the trends in the data.
Discussion
This is the first study to investigate the effect of heat-stabilization treatment on O-glycosylation in human gastric 
tissue. Tissue samples were obtained from patients undergoing gastric cancer surgery (n = 6), for each individual 
a pair of non-tumorigenic and tumorigenic samples were collected to minimize individual differences due to age, 
smoking, body mass index (BMI), medication and other factors which have been reported previously to affect 
the glycosylation of proteins33,34. Each sample was further divided into two fractions post-sampling, one was 
immediately snap-frozen and second one heat-stabilized post-collection and then placed in -80 °C freezer. This 
experimental setup allowed for addressing two aims, a) effect of sample preservation technology on O-glycome 
and b) identification of characteristics differentiating tumor tissue from non-tumor tissue that might lead to clin-
ical tests for detecting, monitoring or treatment of gastric cancer.
Within the field of glycan analysis, sample preparation is often an overlooked but highly important step of pro-
cedure. We have optimized the protocol to ensure efficient extraction of glycoproteins from tissue samples using 
a semi-automatic system. There are many detergents that are currently used in protein solubilisation, including 
anionic and zwitterionic detergents (SDS and CHAPS, respectively) among others. SDS is a routinely used reagent 
for maximum protein solubility and was shown previously to be a superior detergent for extraction of proteins 
during homogenization compared to ASB-13, SB3-10 or CHAPS35. However, due to its charged nature it is incom-
patible with some analyses such as isoelectric focusing (IEF) or acidic protein enrichment. Another important 
consideration for selecting a detergent is the possibility to remove it before analysis as detergents can be prob-
lematic for mass spectrometry. Inability to remove these substances might result in a high chemical background 
and deterioration of the mass spectrometers behavior. Extensive washing needs to be performed prior to glycan 
release as well as additional clean-up prior to LC-MS separation. However, as we noted during sample optimiza-
tion, the glycan distribution was very similar for SDS and CHAPS-treated samples but interfering signals were 
higher for CHAPS. We also observed that sonication had no effect on abundance of O-glycans extracted from 
porcine gastric tissue, so this step was excluded in the analysis of the 24 human samples.
An important strength of the optimized method is the semi-automatic homogenization of tissue samples, 
performed for 24 samples simultaneously. We tested manual homogenization versus a higher throughput homog-
enization with ceramic beads and observed that both provide comparable results. Sample homogenization with 
bead-based technology appears to be a good alternative to the manual homogenization as it provides an increased 
speed and reproducibility of extraction procedures. Recently, several high-throughput workflows have been 
published for large-scale glycoprofiling36–40. These methods were shown to be well-suited for glycan analysis of 
plasma, serum or purified glycoproteins, allowing for automation in the 96-well format. However, they were 
developed for liquid-based matrices that do not require time-consuming homogenization of tissue samples.
Our data showed that O-glycosylation of snap frozen and heat-stabilized samples did not differ. The relative 
abundance of sialylation and sulfation but also other structural features remained the same with the different 
treatments. The data suggest that heat stabilization does not provide any advantage over standard operating pro-
cedures currently employed at the biobanking facility in Siena. However, sample quality can deteriorate rapidly, 
especially if the specimen undergoes multiple thaw/freeze cycles or aliquoting41. In our dataset, there was no 
pre-analytical variability related to processing delays. All samples were collected in a short time, snap frozen or 
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heat-stabilized immediately post-excision and placed in -80 °C freezer. It has been demonstrated previously that 
even a 30 min delay before snap freezing can contribute to a significant decrease in the phosphorylation states42. 
Enzymatic activity is stopped when samples are frozen but once the temperature is raised, the enzymes resume 
their activity and can contribute to unwanted degradation. We could not test what effect thawing/freezing can 
have on glycosylation but in the long term perspective, there is potentially an advantage of using heat-stabilization 
over snap freezing. Heat stabilization inactivates enzymes permanently whereas snap freezing only temporarily. 
Our study analyzed effect of heat stabilization vs. snap freezing on O-glycosylation. However, it would be inter-
esting to test stabilization platform also for other post translational modifications. Heat stabilization has been 
shown to provide superior results over snap freezing for phosphorylated proteins and endogenous peptides43,44. 
Although O-glycosylation profiles appeared to be the same between snap frozen and heat-stabilized tissue, tissue 
stabilization offers the potential to better preserve tissue for other downstream processing and reduce the varia-
bility related to processing delays.
Alterations in gastric cancer protein glycosylation were reported previously in N- and O-glycosylation path-
ways. The majority of glycomic studies performed to date have focused on N-glycans on plasma or serum sam-
ples45,46 but also on purified glycoproteins such as IgG or E-cadherin47,48. The most prominent alterations are 
seen in N-glycan branching and increase in sialylation and fucosylation. Another common feature observed 
in gastrointestinal tumors is the overexpression of short, truncated O-glycans (e.g. Tn, sTn and T antigens) and 
increased sialylation of complex structures (e.g. sLea and sLex antigens) on mucin type O-glycans49,50. However, 
our experimental setup did not allow detecting the Tn-antigen monosaccharide.
High level of structural diversity of human and porcine gastric mucin glycans was reported previously, both 
within individuals and different layers of stomach and regions51,52.
In the current study, comparison of paired tumor and non-tumor tissue samples revealed a number of alter-
ations present in O-glycan structures and derived features. The levels of LacdiNAc epitope were significantly 
reduced in cancerous samples. Interestingly, this epitope was previously found on a secreted MUC5AC on gastric 
mucosa and Kenny et al. showed that it was a dominating structure in gastric normal tissue and possibly protect-
ing against H. pylori binding53–55. In addition, the mean level of % of sialylated structures, as well as individual 
sialylated structures ([M – H]-ions of m/z 675, 878, 966, and 1331) were shown to be increased in cancerous 
samples. This finding is in agreement with previous studies of gastric cancer5. Among significant structures, four 
glycans were significantly decreased in cancerous tissue. The common structural characteristics for all these sam-
ples was blood H-type epitope, α1,2 fucose. This epitope has been previously suggested to inhibit vasculogenesis 
and tumor growth in hepatocarcinoma cells56.
There has always been a trade-off between the sensitivity of fine structure characterization of glycan mixture 
and the ability to perform a high-throughput study of a large number of samples. Paired analysis of tumor and 
neighboring normal gastric mucosa is a valuable methodology employed to identify those changes that can be 
associated with tumorigenesis. Our experimental setup included samples from six individuals that were divided 
into four groups representing different treatment post-collection which allowed us to address two questions a) 
effect of heat stabilization vs. snap freezing of tissue samples post excision and b) alterations between normal and 
cancerous mucosa. The significance of reported alterations for gastric cancer needs to be investigated further on 
a larger cohort. In addition, the heterogeneity of especially the carcinoma tissue indicates that the glycosylation 
changes need to be addressed on subsection based on pathological scoring of tissue section. The O-glycan alter-
ations that are presented here may provide predictive power for the detection and prognosis of gastric cancer. 
Further studies are necessary to determine their clinical potential for improving the accuracy of stomach biopsy 
diagnostics performed in connection to endoscopic examination.
Conclusions
This study shows that there is no significant difference of the gastric O-linked glycans released from post excision 
thermal stabilized tissue and snap frozen tissue. The data also reveal that cancer tissues display different glycosyl-
ation to the adjacent normal tissues. Specifically, tumorigenic tissues appeared to show an increase in sialylation 
and a decrease in LacdiNAc and blood H-type epitope containing glycan structures. As glycosylation impacts on 
many important cellular processes including cellular recognition, protein function, protein stability and immu-
nogenicity, cancer-induced glycosylation changes may trigger a number of downstream effects.
Materials and Methods
Study subjects and clinical description. The study cohort consisted of 6 patients that undergone gastric 
cancer surgery at the Department of General Surgery and Surgical Oncology, University of Siena, Siena, Italy. The 
characteristics of the study group are listed in Table 1. All six individuals were recruited locally, 3 females and 3 
males. The age range for entire cohort was 67–91 years with median age 85. The study conformed to the ethical 
guidelines of the 1975 Declaration of Helsinki and experimental protocols were approved by Comitato Etico 
Regione Toscana. Methods were carried out in accordance with approved protocols with all participants signing 
informed consent prior to participation.
Table 1. Gastric Cancer Patient Clinical Characteristics, stage is indicated using the American Joint Committee 
on Cancer (AJCC) classification, tumor diameter is in mm and the histological classification is based on Lauren’s 
criteria.
Tissue Collecting Conditions. All subjects underwent a surgical procedure with a complete resection of 
the tumor. Depending of the tumor location, distal subtotal gastrectomy was performed or a total gastrectomy 
as described in57,58. Four tissue specimens were collected from each subject (total n = 24), two samples of tumor 
mucosa and two from adjacent normal mucosa. Collected samples were either snap-frozen in liquid nitrogen 
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(n = 12) or heated at 95 °C in the Stabilizor T1 instrument (Denator AB, Uppsala, Sweden) at auto settings for 
fresh tissue (n = 12)10 (Fig. 2). All samples were then transferred to -80 °C until further analysis.
Chemicals and Reagents. Reagent water used throughout this study was obtained from an Elga LabWater 
PureLab flex system (Veolia Water Technologies, High Wycombe, UK) and was 18.2 MΩ or greater with a total 
organic carbon content less than 5 parts per billion. Acetonitrile, methanol and water was of LC-MS grade and 
sodium hydrogen carbonate (NaHCO3) was attained from Merck-Millipore (Darmstadt, Germany). Acetic acid, 
thiourea and sodium dodecyl sulfate (SDS) were from VWR (Radnor, PA, USA). Ammonium bicarbonate ((NH4)
HCO3), sodium borohydride (NaBH4), sodium hydroxide (NaOH), tris, urea, dithiothreitol (DTT), as well as 
iodoacetamide (IAA), was from Sigma-Aldrich (St. Louis, MO, USA).
Sample Homogenization. For optimization of homogenization protocol we have used porcine gastric tis-
sue and several conditions were tested. In particular, manual homogenization with sonication was compared with 
automatic homogenization using Precellys system (Bertin Technologies, Montigny-le Bretonneux, France). For 
the extraction of proteins from porcine gastric tissue, 50 mg (wet weight) sample tissue was weighted, 1 mL of 
solubilisation buffer was added to the tube (7 M urea, 2 M thiourea, 40 mM Tris and a protease inhibitor cocktail 
at the dilution 1:100 (Sigma-Aldrich)) and the tissue was homogenized using a VDI-12 homogenizer (VWR), 
4 × 15 sec, or using a Precellys 24, 2 × 30 sec cycles, samples were kept on ice between the cycles. Homogenization 
was followed by sonication (MSE Soniprep 150, 4 × 15 sek, 16 micron amplitude setting) at 4 °C for one batch 
of the samples but for second batch sonication was not performed to verify if this step was essential for efficient 
tissue homogenization. Further, different concentrations of detergent have been tested (0.5%, 1% and 2%). After 
homogenization, detergent (CHAPS or SDS) and 10 mM DTT were added to the samples to facilitate solubilisa-
tion. Following overnight incubation at 4 °C on a rotor, 25 mM IAA was added and incubated at RT in the dark for 
40 min. Glycan release, desalting and LC-MS analysis of O-linked glycans was performed using the same protocol 
(as described in the subsequent sections) for all the samples.
The snap-frozen and heat stabilized human tissue samples were weighted (50 mg, wet weight) into 2 mL rein-
forced homogenization tubes (Bertin Technologies) and loaded with 6 zirconium oxide beads (3 mm) from Bertin 
Technologies. During weighing, the samples were kept on ice to ensure temperature control during sample han-
dling. The tissue was then homogenized in 500 μL solubilisation buffer (7 M urea, 2 M thiourea, 40 mM Tris and a 
protease inhibitor cocktail at the dilution 1:100 (, Sigma-Aldrich)) at power 5500 using a Precellys 24, 2 repeated 
30-second cycles. Following the homogenization, another 500 μL of solubilisation buffer was added including 
SDS and DTT (final concentration 0.5% SDS and 10 mM DTT). The extraction of up to 2 × 24 tubes was then 
continued at 4 °C overnight on a rotor. After overnight solubilisation, 25 mM IAA was added and incubated for 
40 min at RT in the dark. The tissue extracts were centrifuged for 20 min at 13,200 rpm and the supernatants were 
transferred to a new tube and stored at -20 °C until further analysis.
Glycan Release and Desalting. Tissue extracts (100 μL) were diluted 10 × with buffer (20 mM NaHCO3) 
and applied to a preconditioned 10 kDa cut-off filter (Pall, Port Washington, NY, USA). Samples were centri-
fuged for 10 min at 13,200 rpm, 2 × 500 μL and washed 3 times with 200 μL 20 mM NaHCO3. N-linked glycans 
were released by incubation using 50 μL 20 mM NaHCO3 and PNGaseF (5mU, Prozyme, Hayward, CA) at 37 °C 
overnight. Subsequently, N-glycans were collected by washing 3 times with 50 μL H2O and dried in SpeedVac. 
The O-glycans were then released from retained glycoproteins in filters by incubation with 50 μL 0.5 M NaBH4 in 
50 mM NaOH, 16 hr, at 50 °C59. The reductive β-elimination reaction was quenched by addition of 2.5 μL of acetic 
acid and O-glycans were eluted with 2 × 100 μL H2O and then desalted with 35 μL of AG50WX8 cation exchange 
slurry (Bio-Rad, Hercules, CA) packed on the top of C18 zip tips (Millipore). The samples were then dried in 
the SpeedVac and borate complexes were removed by repeated addition/evaporation of 50 μL of methanol (five 
times). The released oligosaccharides were dissolved in water for LC-MS/MS analysis.
LC- MS/MS of O-linked glycans. Released O-glycans were analyzed by LC-ESI-MS/MS using a 
10 cm × 250 μm I.D. capillary, prepared in-house, containing 5 μm porous graphitized carbon (PGC) particles 
(Thermo Scientific, Waltham, MA). Solvent A was 10 mM (NH4)HCO3 and solvent B was 10 mM (NH4)HCO3 
in 80% acetonitrile. Glycans were eluted using a linear gradient from 0 to 45% buffer B over 45 min at a flow rate 
of 10 μL/min. The eluted O-glycans were detected using a LTQ ion trap mass spectrometer (Thermo Scientific) 
in negative-ion mode with an electrospray voltage of 3.5 kV, capillary voltage of -33.0 V and capillary tempera-
ture of 300 °C. Air was used as a sheath gas and a full scan ranges from m/z 380 to m/z 2000 were defined for the 
structures to be analyzed, selecting 9 most intense ions from the full scan with an intensity of 300 and dynamic 
exclusion for 2 min.
Data Analysis. The O-glycan structures were characterized using accurate monoisotopic precursor mass, 
PGC-LC retention time and collision-induced dissociation (CID)-based MS/MS fragmentation. The data were 
processed using the Xcalibur software (version 2.2, Thermo Scientific) and manually interpreted from their 
MS/MS spectra. The Thermo RAW files were loaded into the Progenesis QI software (Nonlinear Dynamics, 
Newcastle, UK), aligned using automatic alignment and the samples were grouped according to experimental 
conditions (A - normal, STD, B - cancer, STD, C - normal, HEAT, D - cancer, HEAT) using within-subject design. 
Peak picking parameters were set automatic sensitivity with a default noise estimation algorithm and retention 
time limits 7 to 30 min. Compounds without MS/MS spectra were deleted from the analysis, as this information 
in required for structure identification. The compounds were searched against the reference library (developed 
in-house) and downloadable from the UniCarbDB database (http://unicarb-db.expasy.org/)60,61. All compounds 
were manually verified using RT and MS/MS fragmentation. Structures and spectra will be available in next 
update of UniCarbDB at (http://unicarb-db.expasy.org/references/344). Resulting table with compounds of 
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interest and raw abundance was exported to an Excel file for further analysis. In addition to individual structures, 
several derived featrues were calculated. Level of sialylation, sulfation, fucosylation, neutral glycans (Hex and 
HexNAc),LacdiNAc (GalNAcβ1-4GlcNAc), epitopes such as Lewisa/x, Lewisb/y, αGlcNAc, I branch, blood group 
H, A and B were calculated by summing up all structures that contained the same structural trait. Furthermore, 
mass spectrometry average compositions were calculated as described previously62. Briefly, all structures were 
reduced to monosaccharide compositions and were multiplied by percentage intensity for each structure and 
summed over the entire sample.
Statistics. The relative abundance of O-glycan structures is compositional by nature, since the data convey 
the relative percentage areas from the overall O-glycome LC-MS profile rather than absolute quantities. Therefore, 
the data were log-transformed (log(x + 0.1)) to satisfy parametric test assumptions. Paired t-tests were carried out 
to determine if there were significant differences between the groups. Significance levels of t-tests were evaluated 
with a cutoff p-value of 0.05 for the glycan structures and derived glycosylation features and were corrected for 
multiple comparisons using the Benjamini-Hochberg adjustment. Analysis was performed using the R software 
(www.r-project.org) with the R base package and boxplots were constructed using GraphPad Prism 7 software 
(San Francisco, CA, USA).
Data availability. Unprocessed MS files for all the samples are available from local web location according 
to Table S3. MS/MS spectra representative for each assigned structure in Table S2 is available at http://unicarb-db.
expasy.org/references/344).
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